Ligand reactivity and allosteric regulation of hemoglobin-based oxygen carriers

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1784, Issue 10, 2008, Pages 1365-1377

  Ronda, Luca ^a   Bruno, Stefano ^a   Abbruzzetti, Stefania ^a   Viappiani, Cristiano ^a   Bettati, Stefano ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

(propyl PEG2k)6 Hb; (propyl PEG5k)6 Hb; 2,3 diphosphoglicerate; Allosteric properties; bezafibrate; BZF; carbonmonoxy Hb; DPG; HbCO; Hemoglobin; hemoglobin PEGylated with 6 PEG 2000 chains by reductive alkylation chemistry; hemoglobin PEGylated with 6 PEG 5000 chains by reductive alkylation chemistry; IHP; inositol hexaphosphate; Monod, Wyman and Changeux; MWC; nitric oxide; NO; Oxygen binding; oxygen partial pressure; PEG; pO2; polyethylene glycol; Silica gel; Tertiary conformation; Tertiary Two State model; TTS model

Indexed keywords

BEZAFIBRATE; BLOOD SUBSTITUTE; DEOXYHEMOGLOBIN; HEMOGLOBIN; HEMOGLOBIN BASED OXYGEN CARRIER; HEMOGLOBIN GLUTAMER 200; HEMOSPAN; LIPOSOME; MACROGOL; NANOPARTICLE; NITRIC OXIDE; POLYMERIZED HEMOGLOBIN; RECOMBINANT HEMOGLOBIN; UNCLASSIFIED DRUG;

ALLOSTERISM; ANEMIA; CROSS LINKING; DRUG CONJUGATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TREATMENT FAILURE; ENCAPSULATION; ERYTHROCYTE; HUMAN; HYPERTENSION; OXYGEN AFFINITY; OXYGEN TRANSPORT; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; SITE DIRECTED MUTAGENESIS; SURFACE PROPERTY;

ALLOSTERIC REGULATION; BIOPOLYMERS; BLOOD SUBSTITUTES; DRUG STABILITY; EQUIPMENT DESIGN; HEMOGLOBINS; HUMANS; KINETICS; LIGANDS; NANOPARTICLES; OXYHEMOGLOBINS; POINT MUTATION; PROTEIN BINDING;

EID: 52349088745     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2008.04.021     Document Type: Review

References (222)

1. Chang T.M. Blood substitutes based on nanobiotechnology. Trends Biotechnol. 24 (2006) 372-377
2. Stark V. Dtsch. Med. Wochenschr. 24 (1898) 805-808
3. Sellards A.W., and Minot G.R. Injection of hemoglobin in man and its relation to blood distribution, with special reference to the anemias. J. Med. Res. 34 (1916) 469-494
4. Amberson W.R., Jennings J.J., and Rhode C.M. Clinical experience with hemoglobin-saline solutions. J. Appl. Physiol. 1 (1949) 469-489
5. Savitsky J.P., Doczi J., Black J., and Arnold J.D. A clinical safety trial of stroma-free hemoglobin. Clin. Pharmacol. Ther. 23 (1978) 73-80
6. Alayash A.I., D'Agnillo F., and Buehler P.W. First-generation blood substitutes: what have we learned? Biochemical and physiological perspectives. Expert Opin. Biol. Ther. 7 (2007) 665-675
7. Campanini B., Bruno S., Raboni S., and Mozzarelli A. Oxygen delivery via allosteric effectors of hemoglobin, blood substitutes and plasma expanders. In: Abraham D. (Ed). Burger's Medicinal Chemistry. 6th edition vol. 3 (2003), John Wiley and Sons, Inc. 385-442
8. Intaglietta M., Cabrales P., and Tsai A.G. Microvascular perspective of oxygen-carrying and -noncarrying blood substitutes. Annu. Rev. Biomed. Eng. 8 (2006) 289-321
9. Mackenzie C.F., and Bucci C. Artificial oxygen carriers for trauma: myth or reality. Hosp. Med. 65 (2004) 582-588
10. Stowell C.P., Levin J., Spiess B.D., and Winslow R.M. Progress in the development of RBC substitutes. Transfusion 41 (2001) 287-299
11. Vandegriff K.D. Haemoglobin-based oxygen carriers. Expert. Opin. Investig. Drugs 9 (2000) 1967-1984
12. Winslow R.M. Current status of oxygen carriers ('blood substitutes'): 2006. Vox Sang. 91 (2006) 102-110
13. Alayash A.I. Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants?. Nat. Biotechnol. 17 (1999) 545-549
14. Nagababu E., and Rifkind J.M. Reaction of hydrogen peroxide with ferrylhemoglobin: superoxide production and heme degradation. Biochemistry 39 (2000) 12503-12511
15. Nagababu E., and Rifkind J.M. Heme degradation during autoxidation of oxyhemoglobin. Biochem. Biophys. Res. Commun. 273 (2000) 839-845
16. Bunn H.F., and Jandl J.H. Exchange of heme among hemoglobins and between hemoglobin and albumin. J. Biol. Chem. 243 (1968) 465-475
17. Bonaventura J. Clinical implications of the loss of vasoactive nitric oxide during red blood cell storage. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 19165-19166
18. Alayash A.I. Oxygen therapeutics: can we tame haemoglobin?. Nat. Rev. Drug Discov. 3 (2004) 152-159
19. Olson J.S., Foley E.W., Rogge C., Tsai A.L., Doyle M.P., and Lemon D.D. No scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radic. Biol. Med. 36 (2004) 685-697
20. Reiss J.G. Oxygen carriers ("blood substitutes"): raison d'etre, chemistry and some physiology. Chem. Rev. 101 (2001) 2797-2919
21. Winslow R.M. Current status of blood substitute research: towards a new paradigm. J. Intern. Med. 253 (2003) 508-517
22. Crawford J.H., Isbell T.S., Huang Z., Shiva S., Chacko B.K., Schechter A.N., Darley-Usmar V.M., Kerby J.D., Lang Jr. J.D., Kraus D., Ho C., Gladwin M.T., and Patel R.P. Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood 107 (2006) 566-574
23. Vandegriff K.D., Malavalli A., Wooldridge J., Lohman J., and Winslow R.M. MP4, a new nonvasoactive PEG-Hb conjugate. Transfusion 43 (2003) 509-516
24. Winslow R.M. Blood substitutes. Adv. Drug Deliv. Rev. 40 (2000) 131-142
25. Tsai A.G., Acero C., Nance P.R., Cabrales P., Frangos J.A., Buerk D.G., and Intaglietta M. Elevated plasma viscosity in extreme hemodilution increases perivascular nitric oxide concentration and microvascular perfusion. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H1730-H1739
26. Tsoukias N.M., Kavdia M., and Popel A.S. A theoretical model of nitric oxide transport in arterioles: frequency- vs. amplitude-dependent control of cGMP formation. Am. J. Physiol. Heart. Circ. Physiol. 286 (2004) H1043-H1056
27. Stollings J.L., and Oyen L.J. Oxygen therapeutics: oxygen delivery without blood. Pharmacotherapy 26 (2006) 1453-1464
28. Reah G., Bodenham A.R., Mallick A., Daily E.K., and Przybelski R.J. Initial evaluation of diaspirin cross-linked hemoglobin (DCLHb) as a vasopressor in critically ill patients. Crit. Care. Med. 25 (1997) 1480-1488
29. De Angelo J. Nitric oxide scavengers in the treatment of shock associated with systemic inflammatory response syndrome. Expert Opin. Pharmacother. 1 (1999) 19-29
30. Swan S.K., Halstenson C.E., Collins A.J., Colburn W.A., Blue J., and Przybelski R.J. Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients. Am. J. Kidney Dis. 26 (1995) 918-923
31. Kim H.W. Engineering blood cells and proteins as blood substitutes: a short review. Biotechnol. Bioprocess Eng. 12 (2007) 43-47
32. Stowell C.P. Hemoglobin-based oxygen carriers. Curr. Opin. Hematol. 9 (2002) 537-543
33. Winslow R.M. Blood Substitutes (2006), Academic Press Inc., U. S. A.
34. Henry E.R., Bettati S., Hofrichter J., and Eaton W.A. A tertiary two-state allosteric model for hemoglobin. Biophys. Chem. 98 (2002) 149-164
35. Viappiani C., Bettati S., Bruno S., Ronda L., Abbruzzetti S., Mozzarelli A., and Eaton W.A. New insights into allosteric mechanisms from trapping unstable protein conformations in silica gels. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 14414-14419
36. Eaton W.A., Henry E.R., Hofrichter J., Bettati S., Viappiani C., and Mozzarelli A. Evolution of allosteric models for hemoglobin. IUBMB Life 59 (2007) 586-599
37. Eaton W.A., Henry E.R., Hofrichter J., and Mozzarelli A. Is cooperative oxygen binding by hemoglobin really understood?. Nat. Struct. Biol. 6 (1999) 351-358
38. Monod J., Wyman J., and Changeux J.P. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 12 (1965) 88-118
39. Muirhead H., and Perutz M.F. Structure of haemoglobin. A three-dimensional fourier synthesis of reduced human haemoglobin at 5.5 Å resolution. Nature 199 (1963) 633-638
40. Perutz M.F., Bolton W., Diamond R., Muirhead H., and Watson H.C. Structure of haemoglobin. An X-ray examination of reduced horse haemoglobin. Nature 203 (1964) 687-690
41. Pauling L. The oxygen equilibrium of hemoglobin and its structural interpretation. Proc. Natl. Acad. Sci. U. S. A. 21 (1935) 186-191
42. Koshland Jr. D.E., Nemethy G., and Filmer D. Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 5 (1966) 365-385
43. Mozzarelli A., Rivetti C., Rossi G.L., Henry E.R., and Eaton W.A. Crystals of hemoglobin with the T-quarternary structure bind oxygen noncooperatively with no Bohr effect. Nature 351 (1991) 416-419
44. Rivetti C., Mozzarelli A., Rossi G.L., Henry E.R., and Eaton W.A. Oxygen binding by single crystals of hemoglobin. Biochemistry 32 (1993) 2888-2906
45. Bruno S., Bettati S., Manfredini M., Mozzarelli A., Bolognesi M., Deriu D., Rosano C., Tsuneshige A., Yonetani T., and Henry E.R. Oxygen binding by alpha(Fe2+)(2)beta(Ni2+)(2) hemoglobin crystals. Protein Sci. 9 (2000) 683-692
46. Shibayama N., and Saigo S. Fixation of the quaternary structures of human adult haemoglobin by encapsulation in transparent porous silica gels. J. Mol. Biol. 251 (1995) 203-209
47. Bettati S., and Mozzarelli A. T state hemoglobin binds oxygen noncooperatively with allosteric effects of protons, inositol hexaphosphate, and chloride. J. Biol. Chem. 272 (1997) 32050-32055
48. Mozzarelli A., Rivetti C., Rossi G.L., Eaton W.A., and Henry E.R. Allosteric effectors do not alter the oxygen affinity of hemoglobin crystals. Protein Sci. 6 (1997) 484-489
49. Bruno S., Bonaccio M., Bettati S., Rivetti C., Viappiani C., Abbruzzetti S., and Mozzarelli A. High and low oxygen affinity conformations of T state hemoglobin. Protein Sci. 10 (2001) 2401-2407
50. Imai K. Allosteric Effects in Haemoglobin (1982), Cambridge University Press, Cambridge, UK
51. Lalezari I., Lalezari P., Poyart C., Marden M., Kister J., Bohn B., Fermi G., and Perutz M.F. New effectors of human hemoglobin - structure and function. Biochemistry 29 (1990) 1515-1523
52. Kister J., Poyart C., and Edelstein S.J. Oxygen-organophosphate linkage in hemoglobin A. The double hump effect. Biophys. J. 52 (1987) 527-535
53. Kister J., Poyart C., and Edelstein S.J. An expanded two-state allosteric model for interactions of human hemoglobin A with nonsaturating concentrations of 2,3-diphosphoglycerate. J. Biol. Chem. 262 (1987) 12085-12091
54. Marden M.C., Bohn B., Kister J., and Poyart C. Effectors of hemoglobin - separation of allosteric and affinity factors. Biophys. J. 57 (1990) 397-403
55. Yonetani T., Park S., Tsuneshige A., Imai K., and Kanaori K. Global allostery model of hemoglobin - modulation of O2 affinity, cooperativity, and Bohr effect by heterotropic allosteric effectors. J. Biol. Chem. 277 (2002) 34508-34520
56. Tsuneshige A., Park S., and Yonetani T. Heterotropic effectors control the hemoglobin function by interacting with its T and R states - a new view on the principle of allostery. Biophys. Chem. 98 (2002) 49-63
57. Imai K., Tsuneshige A., and Yonetani T. Description of hemoglobin oxygenation under universal solution conditions by a global allostery model with a single adjustable parameter. Biophys. Chem. 98 (2002) 79-91
58. Yonetani T., and Tsuneshige A. The global allostery model of hemoglobin: an allosteric mechanism involving homotropic and heterotropic interactions. C. R. Biol. 326 (2003) 523-532
59. Tsuneshige A., Kanaori K., Samuni U., Danstker D., Friedman J.M., Neya S., Giangiacomo L., and Yonetani T. Semihemoglobins, high oxygen affinity dimeric forms of human hemoglobin respond efficiently to allosteric effectors without forming tetramers. J. Biol. Chem. 279 (2004) 48959-48967
60. Perutz M.F., Fersht A.R., Simon S.R., and Roberts G.C. Influence of globin structure on the state of the heme. II. Allosteric transitions in methemoglobin. Biochemistry 13 (1974) 2174-2186
61. Perutz M.F., Ladner J.E., Simon S.R., and Ho C. Influence of globin structure on the state of the heme. I. Human deoxyhemoglobin. Biochemistry 13 (1974) 2163-2173
62. Ronda L., Bruno S., Viappiani C., Abbruzzetti S., Mozzarelli A., Lowe K.C., and Bettati S. Circular dichroism spectroscopy of tertiary and quaternary conformations of human hemoglobin entrapped in wet silica gels. Protein Sci. 15 (2006) 1961-1967
63. Shibayama N., Miura S., Tame J.R.H., Yonetani T., and Park S.Y. Crystal structure of horse carbonmonoxyhemoglobin-bezafibrate complex at 1.55-angstrom resolution - a novel allosteric binding site in R-state hemoglobin. J. Biol. Chem. 277 (2002) 38791-38796
64. Yokoyama T., Neya S., Tsuneshige A., Yonetani T., Park S.Y., and Tame J.R. R-state haemoglobin with low oxygen affinity: crystal structures of deoxy human and carbonmonoxy horse haemoglobin bound to the effector molecule L35. J. Mol. Biol. 356 (2006) 790-801
65. Perutz M.F., Fermi G., Abraham D.J., Poyart C., and Bursaux E. Hemoglobin as a receptor of drugs and peptides: X-ray studies of the stereochemistry of binding. J. Am. Chem. Soc. 108 (1986) 1064-1078
66. Park S.Y., Yokoyama T., Shibayama N., Shiro Y., and Tame J.R.H. 1.25 Angstrom resolution crystal structures of human haemoglobin in the oxy, deoxy and carbonmonoxy forms. J. Mol. Biol. 360 (2006) 690-701
67. Peterson E.S., Shinder R., Khan I., Juczszak L., Wang J., Manjula B., Acharya S.A., Bonaventura C., and Friedman J.M. Domain-specific effector interactions within the central cavity of human adult hemoglobin in solution and in porous sol-gel matrices: evidence for long-range communication pathways. Biochemistry 43 (2004) 4832-4843
68. Lukin J.A., Kontaxis G., Simplaceanu V., Yuan Y., Bax A., and Ho C. Quaternary structure of hemoglobin in solution. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 517-520
69. Silva M.M., Rogers P.H., and Arnone A. A 3rd quaternary structure of human hemoglobin A at 1.7-Å resolution. J. Biol. Chem. 267 (1992) 17248-17256
70. Mueser T.C., Rogers P.H., and Arnone A. Interface sliding as illustrated by the multiple quaternary structures of liganded hemoglobin. Biochemistry 39 (2000) 15353-15364
71. Safo M.K., and Abraham D.J. The enigma of the liganded hemoglobin end state: a novel quaternary structure of human carbonmonoxy hemoglobin. Biochemistry 44 (2005) 8347-8359
72. Kavanaugh J.S., Rogers P.H., and Arnone A. Crystallographic evidence for a new ensemble of ligand-induced allosteric transitions in hemoglobin: the T-to-T-high quaternary transitions. Biochemistry 44 (2005) 6101-6121
73. Sahu S.C., Simplaceanu V., Gong Q., Ho N.T., Tian F., Prestegard J.H., and Ho C. Insights into the solution structure of human deoxyhemoglobin in the absence and presence of an allosteric effector. Biochemistry 46 (2007) 9973-9980
74. Gong Q.G., Simplaceanu V., Lukin J.A., Giovannelli J.L., Ho N.T., and Ho C. Quaternary structure of carbonmonoxyhemoglobins in solution: structural changes induced by the allosteric effector inositol hexaphosphate. Biochemistry 45 (2006) 5140-5148
75. Chen Q., Lalezari I., Nagel R.L., and H.R.E. Liganded hemoglobin structural perturbations by the allosteric effector L35. Biophys. J. 88 (2005) 2057-2067
76. Shibayama N., and Saigo S. Direct observation of two distinct affinity conformations in the T state human deoxyhemoglobin. FEBS Lett. 429 (2001) 50-53
77. Poyart C.F., Bursaux E., and Bohn B. An estimation of the first binding constant of O2 to human hemoglobin A. Eur. J. Biochem. 87 (1978) 75-83
78. Lyons K.B., Friedman J.M., and Fleury P.A. Nanosecond transient Raman spectra of photolysed carboxyhaemoglobin. Nature 275 (1978) 565-566
79. Hofrichter J., Sommer J.H., Henry E.R., and Eaton W.A. Nanosecond absorption spectroscopy of hemoglobin: elementary processes in kinetic cooperativity. Proc. Natl. Acad. Sci. U. S. A. 80 (1983) 2235-2239
80. Henry E.R., Jones C.M., Hofrichter J., and Eaton W.A. Can a two-state MWC allosteric model explain hemoglobin kinetics?. Biochemistry 36 (1997) 6511-6528
81. Herzfeld J., and Stanley H.E. A general approach to co-operativity and its application to the oxygen equilibrium of hemoglobin and its effectors. J. Mol. Biol. 82 (1974) 231-265
82. Abbruzzetti S., Viappiani C., Bruno S., Bettati S., Bonaccio M., and Mozzarelli A. Functional characterization of heme proteins encapsulated in wet nanoporous silica gels. J. Nanosci. Nanotechnol. 1 (2001) 407-415
83. Shibayama N., and Saigo S. Kinetics of the allosteric transition in hemoglobin within silicate sol-gels. J. Am. Chem. Soc. 121 (1999) 444-445
84. Das T.K., Khan I., Rousseau D.L., and Friedman J.M. Temperature dependent quaternary state relaxation in sol-gel encapsulated hemoglobin. Biospectroscopy 5 (1999) S64-S70
85. Juszczak L.J., and Friedman J.M. UV resonance Raman spectra of ligand binding intermediates of sol-gel encapsulated hemoglobin. J. Biol. Chem. 274 (1999) 30357-30360
86. Khan I., Shannon C.F., Dantsker D., Friedman A.J., Perez-Gonzalez-de-Apodaca J., and Friedman J.M. Sol-gel trapping of functional intermediates of hemoglobin: geminate and bimolecular recombination studies. Biochemistry 39 (2000) 16099-16109
87. Schiro G., and Cupane A. Quaternary relaxations in sol-gel encapsulated hemoglobin studied via NIR and UV spectroscopy. Biochemistry 46 (2007) 11568-11576
88. Brunori M., Coletta M., and Di Cera E. A cooperative model for ligand binding to biological macromolecules as applied to oxygen carriers. Biophys. Chem. 23 (1986) 215-222
89. Gill S.J., Robert C.H., Coletta M., Di Cera E., and Brunori M. Cooperative free energies for nested allosteric models as applied to human hemoglobin. Biophys. J. 50 (1986) 747-752
90. Szabo A., and Karplus M. A mathematical model for structure-function relations in hemoglobin. J. Mol. Biol. 72 (1972) 163-197
91. Perutz M.F. Stereochemistry of cooperative effects in haemoglobin. Nature 228 (1970) 726-739
92. Lee A.W., Karplus M., Poyart C., and Bursaux E. Analysis of proton release in oxygen binding by hemoglobin: implications for the cooperative mechanism. Biochemistry 27 (1988) 1285-1301
93. Friedman J.M. Structure, dynamics, and reactivity in hemoglobin. Science 228 (1985) 1273-1280
94. Friedman J.M., Scott T.W., Fisanick G.J., Simon S.R., Findsen E.W., Ondrias M.R., and Macdonald V.W. Localized control of ligand binding in hemoglobin: effect of tertiary structure on picosecond geminate recombination. Science 229 (1985) 187-190
95. Findsen E.W., Friedman J.M., Ondrias M.R., and Simon S.R. Picosecond time-resolved resonance Raman studies of hemoglobin: implications for reactivity. Science 229 (1985) 661-665
96. Scott T.W., and Friedman J.M. Tertiary-structure relaxation in hemoglobin: a transient Raman study. J. Am. Chem. Soc. 106 (1984) 5677-5687
97. Peterson E.S., and Friedman J.M. A possible allosteric communication pathway identified through a resonance Raman study of four beta37 mutants of human hemoglobin A. Biochemistry 37 (1998) 4346-4357
98. Samuni U., Dantsker D., Juszczak L.J., Bettati S., Ronda L., Mozzarelli A., and Friedman J.M. Spectroscopic and functional characterization of T state hemoglobin conformations encapsulated in silica gels. Biochemistry 43 (2004) 13674-13682
99. Samuni U., Roche C.J., Dantsker D., Juszczak L.J., and Friedman J.M. Modulation of reactivity and conformation within the T-quaternary state of human hemoglobin: the combined use of mutagenesis and sol-gel encapsulation. Biochemistry 45 (2006) 2820-2835
100. Samuni U., Juszczak L., Dantsker D., Khan I., Friedman A.J., Perez-Gonzalez-de-Apodaca J., Bruno S., Hui H.L., Colby J.E., Karasik E., Kwiatkowski L.D., Mozzarelli A., Noble R., and Friedman J.M. Functional and spectroscopic characterization of half-liganded iron-zinc hybrid hemoglobin: evidence for conformational plasticity within the T state. Biochemistry 42 (2003) 8272-8288
101. Samuni U., Roche C.J., Dantsker D., and Friedman J.M. Conformational dependence of hemoglobin reactivity under high viscosity conditions: the role of solvent slaved dynamics. J. Am. Chem. Soc. 129 (2007) 12756-12764
102. Gladwin M.T., Crawford J.H., and Patel R.P. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic. Biol. Med. 36 (2004) 707-717
103. Doyle M.P., and Hoekstra J.W. Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. J. Inorg. Biochem. 14 (1981) 351-358
104. Eich R.F., Li T., Lemon D.D., Doherty D.H., Curry S.R., Aitken J.F., Mathews A.J., Johnson K.A., Smith R.D., Phillips G.N., and Olson J.S. Mechanism of NO-induced oxidation of myoglobin and hemoglobin. Biochemistry 35 (1996) 3385-3395
105. Cooper C.E. Nitric oxide and iron proteins. Biochim. Biophys. Acta 1411 (1999) 290-309
106. Coin J.T., and Olson J.S. The rate of oxygen uptake by human red blood cells. J. Biol. Chem. 254 (1979) 1178-1190
107. Liu X., Miller M.J.S., Joshi M.S., Sadowska-Krowicka H., Clark D.A., and Lancaster J.R. Diffusion-limited reaction of free nitric oxide with erythrocytes. J. Biol. Chem. 273 (1998) 18709-18713
108. Butler A.R., Megson I.L., and Wright P.G. Diffusion of nitric oxide and scavenging by blood in the vasculature. Biochim. Biophys. Acta 1425 (1998) 168-176
109. Vaughn M.W., Kuo L., and Liao J.C. Effective diffusion distance of nitric oxide in the microcirculation. Am. J. Physiol. 274 (1998) H1705-H1714
110. Liao J.C., Hein T.W., Vaughn M.W., Huang K.T., and Kuo L. Intravascular flow decreases erythrocyte consumption of nitric oxide. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 8757-8761
111. Vaughn M.W., Huang K.T., Kuo L., and Liao J.C. Erythrocytes possess an intrinsic barrier to nitric oxide consumption. J. Biol. Chem. 275 (2000) 2342-2348
112. Huang K.T., Han T.H., Hyduke D.R., Vaughn M.W., VanHerle H., Hein T.W., Zhang C., Kuo L., and Liao J.C. Modulation of nitric oxide bioavailability by erythrocytes. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 11771-11776
113. Huang Z., Louderback J.G., Goyal M., Azizi F., King S.B., and Kim-Shapiro D.B. Nitric oxide binding to oxygenated hemoglobin under physiological conditions. Biochim. Biophys. Acta 1568 (2001) 252-260
114. Gladwin M.T., Lancaster J.R., Freeman B.A., and Schechter A.N. Nitric oxides reactions with hemoglobin: a view through the SNO-storm. Nature Med. 9 (2003) 496-500
115. Gow A.J., and Stamler J.S. Reactions between nitric oxide and haemoglobin under physiological conditions. Nature 391 (1998) 169-173
116. Jia L., Bonaventura C., Bonaventura J., and Stamler J.S. S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature 380 (1996) 221-226
117. Pawloski J.R., Hess D.T., and Stamler J.S. Export by red blood cells of nitric oxide bioactivity. Nature 409 (2001) 622-626
118. Stamler J.S., Jia L., Eu J.P., McMahon T.J., Demchenko I.T., Bonaventura J., Gernert K., and Piantadosi C.A. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science 276 (1997) 2034-2037
119. Hobbs A.J., Gladwin M.T., Patel R.P., Williams D.L.H., and Butler A.R. Haemoglobin: NO transporter, NO inactivator or NOne of the above?. Trends Pharmacol. Sci. 23 (2002) 406-411
120. Yonetani T., Tsuneshige A., Zhou Y., and Chen X. Electron paramagnetic resonance and oxygen binding studies of S-nitrosyl hemoglobin. A novel oxygen carrier having NO-assisted allosteric functions. J. Biol. Chem. 273 (1998) 20323-20333
121. Herold S. Interaction of nitrogen monoxide with hemoglobin and the artefactual production of S-nitroso-hemoglobin. C. R. Biol. 326 (2003) 533-541
122. Spencer N.Y., Patel N.K., Keszler A., and Hogg N. Oxidation and nitrosylation of oxyhemoglobin by S-nitrosoglutathione via nitroxyl anion. Free. Radic. Biol. Med. 35 (2003) 1515-1526
123. Zhang Y., and Hogg N. S-nitrosohemoglobin: a biochemical perspective. Free Radic. Biol. Med. 36 (2004) 947-958
124. Pauling L., Itano H.A., et al. Sickle cell anemia a molecular disease. Science 110 (1949) 543-548
125. Bunn H.F., and Forget B.G. Hemoglobin: Molecular, Genetic and Clinical Aspects (1986), W.B. Saunders Company Philadelphia, USA
126. Huisman T.H.J., Carver M.F.H., and Efremov G.D. A Syllabus of Human Hemoglobin Variants (1996), The Sickle Cell Anemia Foundation, Augusta, GA, USA
127. Patrinos G.P., and Wajcman H. Recording human globin gene variation. Hemoglobin 28 (2004) v-vii
128. Bellelli A., Brunori M., Miele A.E., Panetta G., and Vallone B. The allosteric properties of hemoglobin: insights from natural and site directed mutants. Curr. Protein Pept. Sci. 7 (2006) 17-45
129. Gelin B.R., Lee A.W., and Karplus M. Hemoglobin tertiary structural change on ligand binding. Its role in the co-operative mechanism. J. Mol. Bio.l 171 (1983) 489-559
130. Atha D.H., Johnson M.L., and Riggs A.F. The linkage between oxygenation and subunit association in human hemoglobin Kansas. Concentration dependence of the oxygen binding equilibria. J. Biol. Chem. 254 (1979) 12390-12398
131. Moo-Penn W.F., Wolff J.A., Simon G., Vacek M., Jue D.L., and Johnson M.H. Hemoglobin Presbyterian: beta108 (G10) asparagine leads to lysine, a hemoglobin variant with low oxygen affinity. FEBS Lett. 92 (1978) 53-56
132. Kwiatkowski L.D., Hui H.L., Karasik E., Colby J.E., and Noble R.W. Mutations of the betaN102 residue of HbA not only inhibit the ligand-linked T to Re state transition, but also profoundly affect the properties of the T state itself. Biochemistry 46 (2007) 2037-2049
133. Schneider R.G., Atkins R.J., Hosty T.S., Tomlin G., Casey R., Lehmann H., Lorkin P.A., and Nagai K. Haemoglobin Titusville: alpha94 Asp replaced by Asn. A new haemoglobin with a lowered affinity for oxygen. Biochim. Biophys. Acta 400 (1975) 365-373
134. Abdulmalik O., Safo M.K., Lerner N.B., Ochotorena J., Daikhin E., Lakka V., Santacroce R., Abraham D.J., and Asakura T. Characterization of hemoglobin Bassett (alpha94Asp → Ala), a variant with very low oxygen affinity. Am. J. Hematol. 77 (2004) 268-276
135. Antonini E., Wyman J., Zito R., Rossi-Fanelli A., and Caputo A. Studies on carboxypeptidase digests of human hemoglobin. J. Biol. Chem. 236 (1961) PC60-PC63
136. Hewitt J.A., and Gibson Q.H. Ligand binding kinetics of des arginine haemoglobin. J. Mol. Biol. 74 (1973) 489-498
137. Kilmartin J.V., Hewitt J.A., and Wootton J.F. Alteration of functional properties associated with the change in quaternary structure in unliganded haemoglobin. J. Mol. Biol. 93 (1975) 203-218
138. Moffat K., Olson J.S., Gibson Q.H., and Kilmartin J.V. The ligand-binding properties of desHis (146beta) hemoglobin. J. Biol. Chem. 48 (1973) 6387-6393
139. Cheng Y., Shen T.J., Simplaceanu V., and Ho C. Ligand binding properties and structural studies of recombinant and chemically modified hemoglobins altered at beta 93 cysteine. Biochemistry 41 (2002) 11901-11913
140. Vasquez G.B., Karavitis M., Ji X., Pechik I., Brinigar W.S., Gilliland G.L., and Fronticelli C. Cysteines beta93 and beta112 as probes of conformational and functional events at the human hemoglobin subunit interfaces. Biophys. J. 76 (1999) 88-97
141. Bunn H.F., Wohl R.C., Bradley T.B., Cooley M., and Gibson Q.H. Functional properties of hemoglobin Kempsey. J. Biol. Chem. 249 (1974) 7402-7409
142. Reed C.S., Hampson R., Gordon S., Jones R.T., Novy M.J., Brimhall B., Edwards M.J., and Koler R.D. Erythrocytosis secondary to increased oxygen affinity of a mutant hemoglobin, hemoglobin Kempsey. Blood 31 (1968) 623-632
143. Imai K. Hemoglobin Chesapeake (92 alpha, arginine-leucine). Precise measurements and analyses of oxygen equilibrium. J. Biol. Chem. 249 (1974) 7607-7612
144. Carrell R.W., Lehmann H., and Hutchison H.E. Haemoglobin Koln (beta-98 valine-methionine): an unstable protein causing inclusion-body anaemia. Nature 210 (1966) 915-916
145. Pribilla W., Klesse P., Betke K., Lehmann H., and Beale D. Hemoglobin Koln disease: familial hypochromic hemolytic anemia with hemoglobin anomaly. Klin. Wochenschr. 43 (1965) 1049-1053
146. Ohba Y. Unstable hemoglobins. Hemoglobin 14 (1990) 353-388
147. Bonaventura J., Bonaventura C., Giardina B., Antonini E., Brunori M., and Wyman J. Partial restoration of normal functional properties in carboxypeptidase A-digested hemoglobin. Proc. Natl. Acad. Sci. U. S. A. 69 (1972) 2174-2178
148. Looker D., Abbott-Brown D., Cozart P., Durfee S., Hoffman S., Mathews A.J., Miller-Roehrich J., Shoemaker S., Trimble S., Fermi G., et al. A human recombinant haemoglobin designed for use as a blood substitute. Nature 356 (1992) 258-260
149. Brucker E.A. Genetically crosslinked hemoglobin: a structural study. Acta Crystallogr. D Biol. Crystallogr. 56 (2000) 812-816
150. Kroeger K.S., and Kundrot C.E. Structures of a hemoglobin-based blood substitute: insights into the function of allosteric proteins. Structure 5 (1997) 227-237
151. Acharya S.A., Malavalli A., Peterson E., Sun P.D., Ho C., Prabhakaran M., Arnone A., Manjula B.N., and Friedman J.M. Probing the conformation of hemoglobin Presbyterian in the R-state. J. Protein Chem. 22 (2003) 221-230
152. Noble R.W., Kwiatkowski L.D., Hui H.L., Bruno S., Bettati S., and Mozzarelli A. Correlation of protein functional properties in the crystal and in solution: the case study of T-state hemoglobin. Protein Sci. 11 (2002) 1845-1849
153. Jeong S.T., Ho N.T., Hendrich M.P., and Ho C. Recombinant hemoglobin(alpha 29leucine → phenylalanine, alpha 96valine → tryptophan, beta 108asparagine → lysine) exhibits low oxygen affinity and high cooperativity combined with resistance to autoxidation. Biochemistry 38 (1999) 13433-13442
154. Kim H.W., Shen T.J., Sun D.P., Ho N.T., Madrid M., and Ho C. A novel low oxygen affinity recombinant hemoglobin (alpha96Val → Trp): switching quaternary structure without changing the ligation state. J. Mol. Biol. 248 (1995) 867-882
155. Baudin-Creuza V., Fablet C., Zal F., Green B.N., Prome D., Marden M.C., Pagnier J., and Wajcman H. Hemoglobin Porto Alegre forms a tetramer of tetramers superstructure. Protein Sci. 11 (2002) 129-136
156. Fablet C., Marden M.C., Green B.N., Ho C., Pagnier J., and Baudin-Creuza V. Stable octameric structure of recombinant hemoglobin alpha(2)beta(2)83 Gly → Cys. Protein Sci. 12 (2003) 690-695
157. Vasseur-Godbillon C., Sahu S.C., Domingues E., Fablet C., Giovannelli J.L., Tam T.C., Ho N.T., Ho C., Marden M.C., and Baudin-Creuza V. Recombinant hemoglobin betaG83C-F41Y. FEBS J. 273 (2006) 230-241
158. Bobofchak K.M., Mito T., Texel S.J., Bellelli A., Nemoto M., Traystman R.J., Koehler R.C., Brinigar W.S., and Fronticelli C. A recombinant polymeric hemoglobin with conformational, functional, and physiological characteristics of an in vivo O2 transporter. Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H549-H561
159. Fronticelli C., Arosio D., Bobofchak K.M., and Vasquez G.B. Molecular engineering of a polymer of tetrameric hemoglobins. Proteins 44 (2001) 212-222
160. Doherty D.H., Doyle M.P., Curry S.R., Vali R.J., Fattor T.J., Olson J.S., and Lemon D.D. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat. Biotechnol. 16 (1998) 672-676
161. Hartman J.C., Argoudelis G., Doherty D., Lemon D., and Gorczynski R. Reduced nitric oxide reactivity of a new recombinant human hemoglobin attenuates gastric dysmotility. Eur. J. Pharmacol. 363 (1998) 175-178
162. Bakker J.C., Berbers G.A., Bleeker W.K., den Boer P.J., and Biessels P.T. Preparation and characterization of crosslinked and polymerized hemoglobin solutions. Biomater. Artif. Cells Immobil. Biotechnol. 20 (1992) 233-241
163. Richards F.M., and Knowles J.R. Glutaraldehyde as a protein cross-linkage reagent. J. Mol. Biol. 37 (1968) 231-233
164. Walder J.A., Zaugg R.H., Walder R.Y., Steele J.M., and Klotz I.M. Diaspirins that cross-link beta chains of hemoglobin: bis(3,5-dibromosalicyl) succinate and bis(3,5-dibromosalicyl) fumarate. Biochemistry 18 (1979) 4265-4270
165. Chatterjee R., Welty E.V., Walder R.Y., Pruitt S.L., Rogers P.H., Arnone A., and Walder J.A. Isolation and characterization of a new hemoglobin derivative cross-linked between the alpha chains (lysine 99 alpha 1-lysine 99 alpha 2). J. Biol. Chem. 261 (1986) 9929-9937
166. Nacharaju P., Friedman J.M., Prabhakaran M., Acharya S.A., and Manjula B.N. Combining the influence of two low O2 affinity-inducing chemical modifications of the central cavity of hemoglobin. Biochemistry 46 (2007) 4554-4564
167. Nelson D.J. In: Chang T.M.S. (Ed). Blood substitutes: Principles, Methods, Products and Clinical Trials vol. 2 (1998), Karger Landes System, Basel (Switzerland) 39-61
168. Razynska A., Matheson-Urbaitis B., Fronticelli C., Collins J.H., and Bucci E. Stabilization of the tetrameric structure of human and bovine hemoglobins by pseudocrosslinking with muconic acid. Arch. Biochem. Biophys. 326 (1996) 119-125
169. Kwansa H.E., Young A.D., Arosio D., Razynska A., and Bucci E. Adipyl crosslinked bovine hemoglobins as new models of allosteric systems. Proteins 39 (2000) 166-169
170. Fronticelli C., Bucci E., Razynska A., Sznajder J., Urbaitis B., and Gryczynski Z. Bovine hemoglobin pseudo-crosslinked with mono(3,5-dibromosalicyl)-fumarate. Eur. J. Biochem. 193 (1990) 331-336
171. Ji X., Braxenthaler M., Moult J., Fronticelli C., Bucci E., and Gilliland G.L. Conformation of the sebacyl beta1Lys82-beta2Lys82 crosslink in T-state human hemoglobin. Proteins 30 (1998) 309-320
172. Fernandez E.J., Abad-Zapatero C., and Olsen K.W. Crystal structure of Lysbeta(1)82-Lysbeta(2)82 crosslinked hemoglobin: a possible allosteric intermediate. J. Mol. Biol. 296 (2000) 1245-1256
173. D'Agnillo F., and Chang T.M. Cross-linked hemoglobin-superoxide dismutase-catalase scavenges oxygen-derived free radicals and prevents methemoglobin formation and iron release. Biomater. Artif. Cell Immobil. Biotechnol. 21 (1993) 609-621
174. Buehler P.W., Boykins R.A., Jia Y., Norris S., Freedberg D.I., and Alayash A.I. Structural and functional characterization of glutaraldehyde-polymerized bovine hemoglobin and its isolated fractions. Anal. Chem. 77 (2005) 3466-3478
175. Schutte A.E. Ethical considerations concerning South Africa's approval of a blood substitute. Ethics Med. 18 (2002) 55-62
176. Eike J.H., and Palmer A.F. Effect of glutaraldehyde concentration on the physical properties of polymerized hemoglobin-based oxygen carriers. Biotechnol. Prog. 20 (2004) 1225-1232
177. Jahr J.S., and Varma N. PolyHeme. Northfield Laboratories. IDrugs 7 (2004) 478-482
178. Gould S.A., Moore E.E., Hoyt D.B., Burch J.M., Haenel J.B., Garcia J., DeWoskin R., and Moss G.S. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J. Am. Coll. Surgeons 187 (1998) 113-120 discussion 120-122
179. Moss G.S., Gould S.A., Sehgal L.R., Sehgal H.L., and Rosen A.L. Hemoglobin solution-from tetramer to polymer. Surgery 95 (1984) 249-255
180. Sehgal L.R., Gould S.A., Rosen A.L., Sehgal H.L., and Moss G.S. Polymerized pyridoxylated hemoglobin: a red cell substitute with normal oxygen capacity. Surgery 95 (1984) 433-438
181. Boykins R.A., Buehler P.W., Jia Y., Venable R., and Alayash A.I. O-raffinose crosslinked hemoglobin lacks site-specific chemistry in the central cavity: structural and functional consequences of beta93Cys modification. Proteins 59 (2005) 840-855
182. Eike J.H., and Palmer A.F. Oxidized mono-, di-, tri-, and polysaccharides as potential hemoglobin cross-linking reagents for the synthesis of high oxygen affinity artificial blood substitutes. Biotechnol. Prog. 20 (2004) 953-962
183. Haney C.R., Buehler P.W., and Gulati A. Synthesis and characterization of a novel DTPA polymerized hemoglobin based oxygen carrier. Biochim. Biophys. Acta 1725 (2005) 358-369
184. Hu D., and Kluger R. Efficient generation of dendritic arrays of cross-linked hemoglobin: symmetry and redundancy. Org. Biomol. Chem. 6 (2008) 151-156
185. Fronticelli C., Bobofchak K.M., Karavitis M., Sanna M.T., and Brinigar W.S. Introduction of a new regulatory mechanism into human hemoglobin. Biophys. Chem. 98 (2002) 115-126
186. Fronticelli C., Koehler R.C., and Brinigar W.S. Recombinant hemoglobins as artificial oxygen carriers. Artif. Cells Blood Substit. Biotechnol. 35 (2007) 45-52
187. D'Agnillo F., and Chang T.M. Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties. Nature Biotechnol. 16 (1998) 667-671
188. Tarasov E., Blaszak M.M., LaMarre J.M., and Olsen K.W. Synthesis of a hemoglobin polymer containing antioxidant enzymes using complementary chemistry of maleimides and sulfhydryls. Artif. Cells Blood Substit. Immobil. Biotechnol. 35 (2007) 31-43
189. Tam S.C., Blumenstein J., and Wong J.T. Soluble dextran-hemoglobin complex as a potential blood substitute. Proc. Natl. Acad. Sci. U. S. A. 73 (1976) 2128-2131
190. Sacco D., Klett-Zygmunt D., Vigneron C., and Dellacherie E. Covalent fixation of hemoglobin to dextran phosphates decreases its oxygen affinity. Biochim. Biophys. Acta 1041 (1990) 279-284
191. Bonneaux F., Dellacherie E., Labrude P., and Vigneron C. Hemoglobin-dialdehyde dextran conjugates: improvement of their oxygen-binding properties with anionic groups. J. Protein Chem. 15 (1996) 461-465
192. Prouchayret F., and Dellacherie E. Low oxygen affinity derivatives of human hemoglobin by fixation of polycarboxylic dextran to the oxyform. Biopolymers 33 (1993) 1803-1809
193. Bailon P., and Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharmaceut. Sci. Tech. Today 1 (1998) 352-356
194. Schaer D.J., Schaer C.A., Buehler P.W., Boykins R.A., Schoedon G., Alayash A.I., and Schaffner A. CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. Blood 107 (2006) 373-380
195. Iwasaki K., and Iwashita Y. Preparation and evaluation of hemoglobin-polyethylene glycol conjugate (pyridoxalated polyethylene glycol hemoglobin) as an oxygen-carrying resuscitation fluid. Artif. Organs 10 (1986) 411-416
196. Nho K., Linberg R., Johnson M., Gilbert C., and Shorr R. PEG-hemoglobin: an efficient oxygen-delivery system in the rat exchange transfusion and hypovolemic shock models. Artif. Cells Blood Substit. Immobil. Biotechnol. 22 (1994) 795-803
197. Acharya A.S., Manjula B.N., and Smith P.K. Hemoglobin crosslinkers. U.S. Pat. 5 585 (1996) 484
198. Winslow R.M. MP4, a new nonvasoactive polyethylene glycol-hemoglobin conjugate. Artif. Organs 28 (2004) 800-806
199. Manjula B.N., Tsai A.G., Intaglietta M., Tsai C.-H., Ho C., Smith P.K., Perumalsamy K., Kanika N.D., Friedman J.M., and Acharya S.A. Conjugation of multiple copies of polyethylene glycol to hemoglobin facilitated through thiolation: influence on hemoglobin structure and function. Protein J. 24 (2005) 133-146
200. Hu T., Prabhakaran M., Acharya S.A., and Manjula B.N. Influence of the chemistry of conjugation of poly(ethylene glycol) to Hb on the oxygen-binding and solution properties of the PEG-Hb conjugate. Biochem. J. 392 (2005) 555-564
201. Acharya A.S., Sussman L.G., and Manning J.M. Schiff base adducts of glyceraldehyde with hemoglobin. Differences in the Amadori rearrangement at the alpha-amino groups. J. Biol. Chem. 258 (1983) 2296-2302
202. Iafelice R., Cristoni S., Caccia D., Russo R., Rossi-Bernardi L., Lowe K.C., and Perrella M. Identification of the sites of deoxyhaemoglobin PEGylation. Biochem. J. 403 (2007) 189-196
203. Svergun D.I., Ekstrom F., Vandegriff K.D., Malavalli A., Baker D.A., Nilsson C., and Winslow R.M. Solution structure of poly(ethylene) glycol-conjugated hemoglobin revealed by small-angle X-ray scattering: implications for a new oxygen therapeutic. Biophys. J. 94 (2007) 173-181
204. Bruno S., Ronda L., Bettati S., and Mozzarelli A. Trapping hemoglobin in rigid matrices: fine tuning of oxygen binding properties by modulation of encapsulation protocols. Artif. Cells Blood Substit. Immobil. Biotechnol. 35 (2007) 69-79
205. Gill I. Bio-doped nanocomposite polymers: sol-gel bioencapsulates. Chem. Mater. 13 (2001) 3404-3421
206. Bettati S., Pioselli B., Campanini B., Viappiani C., and Mozzarelli A. Protein-doped nanoporous silica gels. In: Nalwa H.S. (Ed). Encyclopedia of Nanoscience and Nanotechnology vol. 9 (2004), American Scientific Publishers 81-103
207. Ellerby L., Nishida C.R., Nishida F., Yamanaka S.A., Dunn B., Valentine J.S., and Zink J.I. Encapsulation of proteins in transparent porous silicate glasses prepared by the sol-gel method. Science 255 (1992) 1113-1115
208. Gill I., and Ballesteros A. Bioencapsulation within synthetic polymers (Part 1): sol-gel encapsulated biologicals. Trends Biotechnol. 18 (2000) 282-296
209. Chang T.M. Modified hemoglobin as red blood cell substitutes. Biomater. Artif. Cell Immobil. Biotechnol. 15 (1987) 323-328
210. Chang T.M. Red blood cell substitutes: microencapsulated hemoglobin and cross-linked hemoglobin including pyridoxylated polyhemoglobin & conjugated hemoglobin. Biomater. Artif. Cell Immobil. Biotechnol. 16 (1988) 11-29
211. Chang T.M. Artificial cells with ultrathin lipid-polymer or lipid-protein membranes. Adv. Exp. Med. Biol. 238 (1988) 215-223
212. Chang T.M. Attempts to find a method to prepare artificial hemoglobin corpuscles. Biomater. Artif. Cell Immobil. Biotechnol. 16 (1988) 1-9
213. Zheng S., Zheng Y., and Beissinger R. Efficacy, physical properties and pharmacokinetics of sterically-stabilized liposome-encapsulated hemoglobin. Artif. Cells Blood Substit. Immobil. Biotechnol. 22 (1994) 487-501
214. Zheng S., Zheng Y., Beissinger R.L., and Fresco R. Microencapsulation of hemoglobin in liposomes using a double emulsion, film dehydration/rehydration approach. Biochim. Biophys. Acta 1196 (1994) 123-130
215. Li S., Nickels J., and Palmer A.F. Liposome-encapsulated actin-hemoglobin (LEAcHb) artificial blood substitutes. Biomaterials 26 (2005) 3759-3769
216. Arifin D.R., and Palmer A.F. Polymersome encapsulated hemoglobin: a novel type of oxygen carrier. Biomacromolecules 6 (2005) 2172-2181
217. Arifin D.R., and Palmer A.F. Physical properties and stability mechanisms of poly(ethylene glycol) conjugated liposome encapsulated hemoglobin dispersions. Artif. Cells Blood Substit. Immobil. Biotechnol. 33 (2005) 137-162
218. Chang T.M. Future generations of red blood cell substitutes. J. Intern. Med. 253 (2003) 527-535
219. Yu W.P., and Chang T.M. Submicron biodegradable polymer membrane hemoglobin nanocapsules as potential blood substitutes: a preliminary report. Artif. Cells Blood Substit. Immobil. Biotechnol. 22 (1994) 889-893
220. Yu W.P., and Chang T.M. Submicron polymer membrane hemoglobin nanocapsules as potential blood substitutes: preparation and characterization. Artif. Cells Blood Substit. Immobil. Biotechnol. 24 (1996) 169-183
221. Chauvierre C., Marden M.C., Vauthier C., Labarre D., Couvreur P., and Leclerc L. Heparin coated poly(alkylcyanoacrylate) nanoparticles coupled to hemoglobin: a new oxygen carrier. Biomaterials 25 (2004) 3081-3086
222. Chauvierre C., Vauthier C., Labarre D., Couvreur P., Marden M.C., and Leclerc L. A new generation of polymer nanoparticles for drug delivery. Cell. Mol. Biol. 50 (2004) 233-239